Indivior Pharmaceuticals Inc (NASDAQ: INDV) Stock Competitors & Peer Comparison
See INDV's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INDV and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INDV | $32.45 | -3.48% | 4B | 8.89 | $3.65 | N/A |
| TAK | $19.67 | +1.13% | 62.2B | 14.16 | $1.39 | +3.59% |
| TEVA | $41.50 | +0.95% | 48.3B | 14.16 | $2.93 | N/A |
| HLN | $10.13 | +1.91% | 44.5B | 20.71 | $0.49 | +1.96% |
| ZTS | $79.38 | +1.22% | 32.8B | 12.06 | $6.58 | +2.65% |
| VTRS | $18.66 | +2.41% | 21.4B | 7.40 | $2.52 | +2.60% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.55 | +0.04% | 11.8B | 22.23 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.07 | +1.32% | 10.9B | 27.79 | $0.47 | +0.64% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
INDV vs TAK Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TAK has a market cap of 62.2B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TAK trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TAK's P/E ratio is 14.16. In terms of profitability, INDV's ROE is -2.16%, compared to TAK's ROE of +0.02%. Regarding short-term risk, INDV is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for INDV.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
INDV vs TEVA Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TEVA has a market cap of 48.3B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TEVA trades at $41.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TEVA's P/E ratio is 14.16. In terms of profitability, INDV's ROE is -2.16%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, INDV is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for INDV.Check TEVA's competition here
Haleon plc (NYSE: HLN)
INDV vs HLN Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while HLN trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas HLN's P/E ratio is 20.71. In terms of profitability, INDV's ROE is -2.16%, compared to HLN's ROE of +0.10%. Regarding short-term risk, INDV is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for INDV.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
INDV vs ZTS Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ZTS has a market cap of 32.8B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ZTS trades at $79.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ZTS's P/E ratio is 12.06. In terms of profitability, INDV's ROE is -2.16%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, INDV is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
INDV vs VTRS Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, VTRS has a market cap of 21.4B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while VTRS trades at $18.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas VTRS's P/E ratio is 7.40. In terms of profitability, INDV's ROE is -2.16%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, INDV is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for INDV.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
INDV vs ITCI Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ITCI's P/E ratio is -180.64. In terms of profitability, INDV's ROE is -2.16%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, INDV is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
INDV vs ELAN Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ELAN trades at $23.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ELAN's P/E ratio is 22.23. In terms of profitability, INDV's ROE is -2.16%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, INDV is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
INDV vs CTLT Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas CTLT's P/E ratio is -27.84. In terms of profitability, INDV's ROE is -2.16%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, INDV is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for INDV.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
INDV vs RDY Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while RDY trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas RDY's P/E ratio is 27.79. In terms of profitability, INDV's ROE is -2.16%, compared to RDY's ROE of +0.09%. Regarding short-term risk, INDV is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for INDV.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
INDV vs ALKS Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ALKS has a market cap of 6.9B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ALKS trades at $41.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ALKS's P/E ratio is 43.39. In terms of profitability, INDV's ROE is -2.16%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, INDV is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
INDV vs LNTH Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while LNTH trades at $99.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas LNTH's P/E ratio is 16.76. In terms of profitability, INDV's ROE is -2.16%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, INDV is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for INDV.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
INDV vs AMRX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, AMRX has a market cap of 6.1B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while AMRX trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas AMRX's P/E ratio is 21.31. In terms of profitability, INDV's ROE is -2.16%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, INDV is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for INDV.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
INDV vs RGC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, RGC has a market cap of 4.8B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while RGC trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas RGC's P/E ratio is -959.00. In terms of profitability, INDV's ROE is -2.16%, compared to RGC's ROE of -1.61%. Regarding short-term risk, INDV is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for INDV.Check RGC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
INDV vs HCM Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while HCM trades at $14.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas HCM's P/E ratio is 135.88. In terms of profitability, INDV's ROE is -2.16%, compared to HCM's ROE of +0.01%. Regarding short-term risk, INDV is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for INDV.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
INDV vs ALVOW Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, INDV's ROE is -2.16%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, INDV is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
INDV vs BHC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while BHC trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas BHC's P/E ratio is 1.60. In terms of profitability, INDV's ROE is -2.16%, compared to BHC's ROE of +0.89%. Regarding short-term risk, INDV is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for INDV.Check BHC's competition here
Perrigo Company plc (NYSE: PRGO)
INDV vs PRGO Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while PRGO trades at $16.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas PRGO's P/E ratio is 6.65. In terms of profitability, INDV's ROE is -2.16%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, INDV is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for INDV.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
INDV vs DCPH Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas DCPH's P/E ratio is -11.58. In terms of profitability, INDV's ROE is -2.16%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, INDV is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for INDV.Check DCPH's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
INDV vs SUPN Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, SUPN has a market cap of 2.2B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while SUPN trades at $37.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas SUPN's P/E ratio is 12.38. In terms of profitability, INDV's ROE is -2.16%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, INDV is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for INDV.Check SUPN's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
INDV vs AVDL Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, INDV's ROE is -2.16%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, INDV is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for INDV.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
INDV vs EMBCV Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas EMBCV's P/E ratio is N/A. In terms of profitability, INDV's ROE is -2.16%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, INDV is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for INDV.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
INDV vs DVAX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas DVAX's P/E ratio is -41.89. In terms of profitability, INDV's ROE is -2.16%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, INDV is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for INDV.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
INDV vs ALVO Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ALVO trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ALVO's P/E ratio is -8.47. In terms of profitability, INDV's ROE is -2.16%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, INDV is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for INDV.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
INDV vs TRLV Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TRLV trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TRLV's P/E ratio is -4.07. In terms of profitability, INDV's ROE is -2.16%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, INDV is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for INDV.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
INDV vs ANIP Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ANIP trades at $72.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ANIP's P/E ratio is 8.79. In terms of profitability, INDV's ROE is -2.16%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, INDV is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
INDV vs TARO Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TARO's P/E ratio is 30.05. In terms of profitability, INDV's ROE is -2.16%, compared to TARO's ROE of +0.03%. Regarding short-term risk, INDV is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for INDV.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
INDV vs PAHC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while PAHC trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas PAHC's P/E ratio is 13.25. In terms of profitability, INDV's ROE is -2.16%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, INDV is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for INDV.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
INDV vs PCRX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while PCRX trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas PCRX's P/E ratio is 13.98. In terms of profitability, INDV's ROE is -2.16%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, INDV is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for INDV.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
INDV vs ETON Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ETON trades at $50.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ETON's P/E ratio is 132.34. In terms of profitability, INDV's ROE is -2.16%, compared to ETON's ROE of +0.40%. Regarding short-term risk, INDV is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for INDV.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
INDV vs CRON Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while CRON trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas CRON's P/E ratio is 16.44. In terms of profitability, INDV's ROE is -2.16%, compared to CRON's ROE of +0.06%. Regarding short-term risk, INDV is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for INDV.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
INDV vs AMPH Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while AMPH trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas AMPH's P/E ratio is 8.83. In terms of profitability, INDV's ROE is -2.16%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, INDV is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for INDV.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
INDV vs HROW Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, HROW has a market cap of 1B. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while HROW trades at $27.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas HROW's P/E ratio is -27.56. In terms of profitability, INDV's ROE is -2.16%, compared to HROW's ROE of -1.04%. Regarding short-term risk, INDV is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for INDV.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
INDV vs PETQ Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas PETQ's P/E ratio is 83.73. In terms of profitability, INDV's ROE is -2.16%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, INDV is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for INDV.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
INDV vs COLL Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, COLL has a market cap of 755M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while COLL trades at $23.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas COLL's P/E ratio is 2.91. In terms of profitability, INDV's ROE is -2.16%, compared to COLL's ROE of +0.16%. Regarding short-term risk, INDV is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for INDV.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
INDV vs IRWD Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, IRWD has a market cap of 578.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while IRWD trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas IRWD's P/E ratio is 4.49. In terms of profitability, INDV's ROE is -2.16%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, INDV is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for INDV.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
INDV vs BDSI Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas BDSI's P/E ratio is 6.82. In terms of profitability, INDV's ROE is -2.16%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, INDV is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for INDV.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
INDV vs EVO Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, EVO has a market cap of 491.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while EVO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas EVO's P/E ratio is -1.96. In terms of profitability, INDV's ROE is -2.16%, compared to EVO's ROE of -0.27%. Regarding short-term risk, INDV is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for INDV.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
INDV vs AQST Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, AQST has a market cap of 473.8M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while AQST trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas AQST's P/E ratio is -5.81. In terms of profitability, INDV's ROE is -2.16%, compared to AQST's ROE of +2.44%. Regarding short-term risk, INDV is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for INDV.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
INDV vs EOLS Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, EOLS has a market cap of 468.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while EOLS trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas EOLS's P/E ratio is -22.45. In terms of profitability, INDV's ROE is -2.16%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, INDV is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for INDV.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
INDV vs KMDA Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, KMDA has a market cap of 446.6M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while KMDA trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas KMDA's P/E ratio is 20.37. In terms of profitability, INDV's ROE is -2.16%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, INDV is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for INDV.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
INDV vs TKNO Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TKNO has a market cap of 380.1M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TKNO trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TKNO's P/E ratio is -22.84. In terms of profitability, INDV's ROE is -2.16%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, INDV is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for INDV.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
INDV vs TLRY Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TLRY has a market cap of 340M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TLRY trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TLRY's P/E ratio is -2.17. In terms of profitability, INDV's ROE is -2.16%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, INDV is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for INDV.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
INDV vs EBS Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, EBS has a market cap of 326.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while EBS trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas EBS's P/E ratio is 4.43. In terms of profitability, INDV's ROE is -2.16%, compared to EBS's ROE of -0.36%. Regarding short-term risk, INDV is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for INDV.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
INDV vs CGC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, CGC has a market cap of 301.7M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while CGC trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas CGC's P/E ratio is -1.60. In terms of profitability, INDV's ROE is -2.16%, compared to CGC's ROE of -0.33%. Regarding short-term risk, INDV is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for INDV.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
INDV vs ALIM Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ALIM's P/E ratio is 5.28. In terms of profitability, INDV's ROE is -2.16%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, INDV is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ALIM's competition here
Glass House Brands Inc (NYSE: GLAS)
INDV vs GLAS Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, GLAS has a market cap of 279.8M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while GLAS trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas GLAS's P/E ratio is -5.68. In terms of profitability, INDV's ROE is -2.16%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, INDV is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for INDV.Check GLAS's competition here
Landec Corporation (NASDAQ: LNDC)
INDV vs LNDC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas LNDC's P/E ratio is -4.04. In terms of profitability, INDV's ROE is -2.16%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, INDV is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for INDV.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
INDV vs ACB Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ACB has a market cap of 252.6M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ACB trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ACB's P/E ratio is -2.88. In terms of profitability, INDV's ROE is -2.16%, compared to ACB's ROE of -0.21%. Regarding short-term risk, INDV is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
INDV vs LFCR Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, LFCR has a market cap of 241.8M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while LFCR trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas LFCR's P/E ratio is -5.02. In terms of profitability, INDV's ROE is -2.16%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, INDV is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for INDV.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
INDV vs TYHT Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TYHT's P/E ratio is -1.61. In terms of profitability, INDV's ROE is -2.16%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, INDV is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for INDV.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
INDV vs SIGA Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, SIGA has a market cap of 227.8M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while SIGA trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas SIGA's P/E ratio is 11.74. In terms of profitability, INDV's ROE is -2.16%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, INDV is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for INDV.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
INDV vs REPH Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas REPH's P/E ratio is -8.04. In terms of profitability, INDV's ROE is -2.16%, compared to REPH's ROE of -0.22%. Regarding short-term risk, INDV is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for INDV.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
INDV vs THTX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas THTX's P/E ratio is -28.83. In terms of profitability, INDV's ROE is -2.16%, compared to THTX's ROE of +0.36%. Regarding short-term risk, INDV is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for INDV.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
INDV vs ASRT Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ASRT's P/E ratio is -7.10. In terms of profitability, INDV's ROE is -2.16%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, INDV is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
INDV vs DERM Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, DERM has a market cap of 139.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while DERM trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas DERM's P/E ratio is -22.52. In terms of profitability, INDV's ROE is -2.16%, compared to DERM's ROE of -0.20%. Regarding short-term risk, INDV is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for INDV.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
INDV vs CRDL Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while CRDL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas CRDL's P/E ratio is -4.38. In terms of profitability, INDV's ROE is -2.16%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, INDV is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for INDV.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
INDV vs OGI Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, OGI has a market cap of 130.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while OGI trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas OGI's P/E ratio is 2.09. In terms of profitability, INDV's ROE is -2.16%, compared to OGI's ROE of +0.21%. Regarding short-term risk, INDV is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for INDV.Check OGI's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
INDV vs ORGO Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ORGO has a market cap of 128.6M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ORGO trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ORGO's P/E ratio is 33.32. In terms of profitability, INDV's ROE is -2.16%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, INDV is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for INDV.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
INDV vs SCTL Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas SCTL's P/E ratio is -7.86. In terms of profitability, INDV's ROE is -2.16%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, INDV is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for INDV.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
INDV vs BGM Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, BGM has a market cap of 110.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while BGM trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas BGM's P/E ratio is -1.81. In terms of profitability, INDV's ROE is -2.16%, compared to BGM's ROE of -0.05%. Regarding short-term risk, INDV is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for INDV.Check BGM's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
INDV vs CPIX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, CPIX has a market cap of 107.6M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while CPIX trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas CPIX's P/E ratio is -17.95. In terms of profitability, INDV's ROE is -2.16%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, INDV is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for INDV.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
INDV vs PROC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas PROC's P/E ratio is 1.53. In terms of profitability, INDV's ROE is -2.16%, compared to PROC's ROE of -2.22%. Regarding short-term risk, INDV is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for INDV.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
INDV vs OPTN Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas OPTN's P/E ratio is -4.42. In terms of profitability, INDV's ROE is -2.16%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, INDV is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for INDV.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
INDV vs ZOM Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ZOM's P/E ratio is -1.62. In terms of profitability, INDV's ROE is -2.16%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, INDV is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for INDV.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
INDV vs GRVI Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas GRVI's P/E ratio is 26.05. In terms of profitability, INDV's ROE is -2.16%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, INDV is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for INDV.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
INDV vs ZYNE Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, INDV's ROE is -2.16%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, INDV is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for INDV.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
INDV vs ZYBT Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ZYBT has a market cap of 69.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ZYBT trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ZYBT's P/E ratio is -7.30. In terms of profitability, INDV's ROE is -2.16%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, INDV is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for INDV.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
INDV vs SSIC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas SSIC's P/E ratio is 11.93. In terms of profitability, INDV's ROE is -2.16%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, INDV is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for INDV.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
INDV vs VLNS Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas VLNS's P/E ratio is -1.03. In terms of profitability, INDV's ROE is -2.16%, compared to VLNS's ROE of N/A. Regarding short-term risk, INDV is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for INDV.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
INDV vs DRRX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas DRRX's P/E ratio is -4.44. In terms of profitability, INDV's ROE is -2.16%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, INDV is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for INDV.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
INDV vs TLPH Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TLPH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TLPH's P/E ratio is -4.00. In terms of profitability, INDV's ROE is -2.16%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, INDV is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for INDV.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
INDV vs INCR Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, INCR has a market cap of 54.1M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while INCR trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas INCR's P/E ratio is -4.81. In terms of profitability, INDV's ROE is -2.16%, compared to INCR's ROE of -0.09%. Regarding short-term risk, INDV is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for INDV.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
INDV vs JUPW Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas JUPW's P/E ratio is -2.41. In terms of profitability, INDV's ROE is -2.16%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, INDV is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for INDV.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
INDV vs QLI Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas QLI's P/E ratio is -4.92. In terms of profitability, INDV's ROE is -2.16%, compared to QLI's ROE of -0.16%. Regarding short-term risk, INDV is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for INDV.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
INDV vs HEXO Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas HEXO's P/E ratio is -0.26. In terms of profitability, INDV's ROE is -2.16%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, INDV is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for INDV.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
INDV vs RMTI Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, RMTI has a market cap of 29.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while RMTI trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas RMTI's P/E ratio is -5.54. In terms of profitability, INDV's ROE is -2.16%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, INDV is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for INDV.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
INDV vs CPHI Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, CPHI has a market cap of 29.4M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while CPHI trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas CPHI's P/E ratio is -1.59. In terms of profitability, INDV's ROE is -2.16%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, INDV is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for INDV.Check CPHI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
INDV vs SHPH Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, SHPH has a market cap of 24.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while SHPH trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas SHPH's P/E ratio is -0.24. In terms of profitability, INDV's ROE is -2.16%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, INDV is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for INDV.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
INDV vs CYTH Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas CYTH's P/E ratio is -0.80. In terms of profitability, INDV's ROE is -2.16%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, INDV is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for INDV.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
INDV vs AYTU Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, AYTU has a market cap of 22.1M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while AYTU trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas AYTU's P/E ratio is -1.72. In terms of profitability, INDV's ROE is -2.16%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, INDV is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for INDV.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
INDV vs TXMD Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, TXMD has a market cap of 22M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while TXMD trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas TXMD's P/E ratio is 96.79. In terms of profitability, INDV's ROE is -2.16%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, INDV is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for INDV.Check TXMD's competition here
Optimi Health Corp. (NASDAQ: OPTH)
INDV vs OPTH Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, OPTH has a market cap of 19.4M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while OPTH trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas OPTH's P/E ratio is -2.17. In terms of profitability, INDV's ROE is -2.16%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, INDV is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for INDV.Check OPTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
INDV vs EVOK Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas EVOK's P/E ratio is -7.97. In terms of profitability, INDV's ROE is -2.16%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, INDV is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for INDV.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
INDV vs ACRX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ACRX's P/E ratio is -0.31. In terms of profitability, INDV's ROE is -2.16%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, INDV is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for INDV.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
INDV vs CABR Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, CABR has a market cap of 11.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while CABR trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas CABR's P/E ratio is -1.58. In terms of profitability, INDV's ROE is -2.16%, compared to CABR's ROE of -3.86%. Regarding short-term risk, INDV is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for INDV.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
INDV vs AGRX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas AGRX's P/E ratio is -0.89. In terms of profitability, INDV's ROE is -2.16%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, INDV is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for INDV.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
INDV vs NLTX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas NLTX's P/E ratio is -0.28. In terms of profitability, INDV's ROE is -2.16%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, INDV is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for INDV.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
INDV vs LCI Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas LCI's P/E ratio is -0.04. In terms of profitability, INDV's ROE is -2.16%, compared to LCI's ROE of +1.66%. Regarding short-term risk, INDV is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for INDV.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
INDV vs ADMP Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ADMP's P/E ratio is -0.08. In terms of profitability, INDV's ROE is -2.16%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, INDV is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for INDV.Check ADMP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
INDV vs INM Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, INM has a market cap of 7.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while INM trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas INM's P/E ratio is -0.43. In terms of profitability, INDV's ROE is -2.16%, compared to INM's ROE of -1.35%. Regarding short-term risk, INDV is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for INDV.Check INM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
INDV vs SNOA Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, SNOA has a market cap of 5.5M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas SNOA's P/E ratio is -1.04. In terms of profitability, INDV's ROE is -2.16%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, INDV is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for INDV.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
INDV vs MNK Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas MNK's P/E ratio is -0.44. In terms of profitability, INDV's ROE is -2.16%, compared to MNK's ROE of -0.36%. Regarding short-term risk, INDV is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for INDV.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
INDV vs FLGC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas FLGC's P/E ratio is -0.19. In terms of profitability, INDV's ROE is -2.16%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, INDV is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for INDV.Check FLGC's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
INDV vs GELS Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, GELS has a market cap of 4.2M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while GELS trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas GELS's P/E ratio is -1.05. In terms of profitability, INDV's ROE is -2.16%, compared to GELS's ROE of -0.25%. Regarding short-term risk, INDV is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for INDV.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
INDV vs YCBD Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, YCBD has a market cap of 3.8M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while YCBD trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas YCBD's P/E ratio is -0.84. In terms of profitability, INDV's ROE is -2.16%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, INDV is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for INDV.Check YCBD's competition here
Akanda Corp. (NASDAQ: AKAN)
INDV vs AKAN Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, AKAN has a market cap of 2.9M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while AKAN trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas AKAN's P/E ratio is -0.03. In terms of profitability, INDV's ROE is -2.16%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, INDV is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for INDV.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
INDV vs PLXP Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas PLXP's P/E ratio is -0.22. In terms of profitability, INDV's ROE is -2.16%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, INDV is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for INDV.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
INDV vs UPC Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while UPC trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas UPC's P/E ratio is -0.49. In terms of profitability, INDV's ROE is -2.16%, compared to UPC's ROE of -0.03%. Regarding short-term risk, INDV is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for INDV.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
INDV vs ATNX Comparison October 2026
Indivior Pharmaceuticals Inc (NASDAQ: INDV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDV stands at 4B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, INDV is priced at $32.45 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDV currently has a P/E ratio of 8.89, whereas ATNX's P/E ratio is -0.02. In terms of profitability, INDV's ROE is -2.16%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, INDV is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for INDV.Check ATNX's competition here